Er-Positive, Her2-Negative Advanced Breast Cancer

SAN ANTONIO — Imlunestrant alone or as part of combination therapy extended PFS for certain patients with advanced breast cancer resistant to hormone therapy, according to study results presented at San Antonio Breast Cancer Symposium.